Intelligent Bio Solutions (INBS) AI Stock Analysis

• Market Cap: $8.85M
• Dividend Yield: N/A
• Average Volume (3M): 101.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.25
• Revenue Growth: 3.87%
• EPS Growth: 35.37%
• Country: US
• Employees: 50
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.44
• Shares Outstanding: 6,910,279
• 10 Day Avg. Volume: 174,734
• 30 Day Avg. Volume: 101,505
• PEG Ratio: -0.02
• Price to Book (P/B): 1.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $1.00 ▼( -22.48% Downside)

INBS shows promising revenue growth and strategic expansion, particularly with global operations and securing a U.S. patent. However, persistent negative earnings, weak cash flows, and bearish technical indicators weigh heavily on the stock's attractiveness. The negative valuation metrics also pose significant concerns, needing resolution for improved investor confidence.

Intelligent Bio Solutions Business Overview & Revenue Model

Company Description

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

How the Company Makes Money

Intelligent Bio Solutions makes money through the sale of its diagnostic tools and therapeutic platforms to healthcare providers, research institutions, and other entities within the biotech industry. The company generates revenue through direct product sales, licensing agreements, and collaborations with strategic partners. These partnerships may include research and development collaborations where INBS receives funding or milestone payments in exchange for access to its proprietary technology. Additionally, the company may engage in service contracts where it provides specialized testing or research services to its clients.

Intelligent Bio Solutions Financial Statement Overview

Summary

Intelligent Bio Solutions is experiencing revenue growth and improvements in gross profit, but it faces challenges due to persistent negative earnings and cash flow. The balance sheet is relatively stable with a manageable debt level, yet the company must focus on improving profitability and cash generation to enhance its financial standing.

Income Statement

INBS has shown a significant improvement in revenue over the past years, with a notable increase in gross profit margin compared to previous periods. However, the company is still struggling with negative EBIT and net income, leading to negative profit margins. The revenue growth is promising, yet profitability remains a key challenge.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio and a positive equity position, indicating some stability. Stockholders' equity has improved, providing a cushion for liabilities. However, the company needs to address its significant liabilities to improve financial health further.

Cash Flow

INBS has a negative operating cash flow, which raises concerns about its ability to generate cash from operations. The free cash flow is also negative, although there has been a recent influx of financing cash flow. The company needs to improve cash generation to ensure long-term sustainability.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
3.03M	3.11M	1.26M	0.00	1.98M	188.74K
	Gross Profit
1.25M	1.43M	326.67K	0.00	1.98M	188.74K
	EBIT
-10.84M	-10.28M	-12.60M	-8.34M	-5.57M	-2.71M
	EBITDA
-9.47M	-8.81M	-9.47M	30.82K	-1.82M	-561.19K
	Net Income Common Stockholders
-10.69M	-10.16M	-10.63M	-8.31M	-7.04M	-3.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.24M	6.30M	1.54M	8.24M	12.57M	427.27K
	Total Assets
8.68M	13.78M	10.35M	12.35M	20.40M	2.48M
	Total Debt
626.01K	871.44K	1.34M	0.00	0.00	5.13M
	Net Debt
-1.62M	-5.43M	-201.56K	-8.24M	-12.57M	4.71M
	Total Liabilities
4.48M	5.60M	6.67M	5.81M	6.85M	7.69M
	Stockholders Equity
4.37M	8.33M	3.80M	6.62M	13.61M	-5.19M
Cash Flow		Free Cash Flow
-7.82M	-9.79M	-7.88M	-3.74M	-11.30M	-498.62K
	Operating Cash Flow
-10.12M	-9.57M	-7.38M	-3.36M	-11.30M	-498.62K
	Investing Cash Flow
-176.24K	-221.43K	-694.14K	-880.22K	0.00	-14.00K
	Financing Cash Flow
11.50M	14.56M	1.44M	0.00	23.40M	733.86K

Intelligent Bio Solutions Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Neutral. The current price of 1.29 is above the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.44, and below the 200-day MA of 1.58, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 46.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INBS.

Intelligent Bio Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	66 Neutral	$13.58M	―	-25.29%	―	26.67%	44.02%
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
INBS	49 Neutral	$8.85M	―	-126.34%	―	3.87%	35.37%
STRR	48 Neutral	$6.96M	―	-15.34%	―	34.33%	-153.90%
MYNZ	42 Neutral	$6.38M	―	-809.29%	―	―	―
BIAF	42 Neutral	$7.50M	―	-290.85%	―	78.40%	22.41%
CHEK	26 Underperform	$5.23M	―	-74.17%	―	―	―

Intelligent Bio Solutions Corporate Events

Intelligent Bio Solutions Expands Global Operations

On May 15, 2025, Intelligent Bio Solutions Inc. announced significant growth in its global operations, driven by new account acquisitions and expansion into new testing areas and sectors. The company now has over 450 active accounts across 24 countries, with notable expansion into the luxury marine sector in Europe and various sectors in Australia. These developments align with the company’s strategic plans for international expansion and strengthen its foundation ahead of entering the U.S. market.

Intelligent Bio Solutions Reports Strong Q3 2025 Results

On May 13, 2025, Intelligent Bio Solutions Inc. announced its financial results for the fiscal third quarter and nine months ended March 31, 2025. The company reported a 20% sequential quarterly revenue growth and a 91% year-over-year increase in quarterly gross profit, driven by higher-margin cartridge sales, which now account for 58% of total sales. The company added 35 new accounts, bringing its total active accounts to over 450, and continued its international growth strategy with expansions in Europe and the Middle East. The company also announced a reduction in losses due to improved cost control and operational efficiency, and introduced multilingual functionality to support global scalability.

Intelligent Bio Solutions Secures U.S. Patent for Drug Screening

On March 26, 2025, Intelligent Bio Solutions Inc. announced the granting of a U.S. patent for its Intelligent Fingerprinting Drug Screening Cartridge, marking its sixth active U.S. patent. This patent strengthens the company’s intellectual property portfolio and competitive position as it plans to enter the multi-billion dollar U.S. market in 2025. The patent covers the lateral flow test strip technology used in the company’s drug screening system, which detects drugs in fingerprint sweat. This development is part of INBS’s strategy to leverage the expanding global drug screening market, with a recent FDA 510(k) submission and plans for U.S. market entry.

Intelligent Bio Solutions Anticipates Sixth U.S. Patent Approval

On March 20, 2025, Intelligent Bio Solutions Inc. announced its expectation to receive a sixth U.S. patent, enhancing its intellectual property portfolio for its lateral flow technology used in the Intelligent Fingerprinting Drug Testing Solution. This development is crucial for the company’s strategy to expand its presence in the U.S. drug screening market, as it aims to meet the growing demand for non-invasive testing solutions. The anticipated patent will help protect the company’s proprietary technology as it prepares for U.S. market entry in 2025, positioning it to drive industry transformation and expand its global market presence.